Sugemalimab
As of the edition of 20 October 2026, Sugemalimab is an antibody: marketed, first approved in 2024 (EU); acts on CD274.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Antibody
- Brand name
- Cejemly
- First approved
- 24 July 2024 (EU)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- CStone Pharmaceuticals
- Registered trials
- 20, 0 stopped early
- Disease areas
- Cancer; Lungs and airways; Digestive system; Blood and lymph; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Sugemalimab.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD274 | Programmed cell death 1 ligand 1 | Q9NZQ7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 1 | 0 |
| Phase 1 | 5 | 3 | 1 | 0 |
| Phase 2 | 7 | 4 | 3 | 0 |
| Phase 3 | 6 | 4 | 2 | 0 |
| All trials | 20 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| CStone Pharmaceuticals | Applicant and Lead sponsor of trials | 2017 to now |